Show notes
Brendon Neuen, MBBS, PhD, joins hosts to discuss the landmark FLOW trial and its implications on the future of chronic kidney disease management as well as other compelling data surrounding semaglutide from the 61st European Renal Association Congress. Key Highlights:00:00 - Intro01:12 - ERA Recap 03:06 - FLOW Background05:20 - FLOW Results06:56 - FLOW Reaction (Neuen)09:13 - Semaglutide Mortality Benefit12:43 - Semaglutide 2.4 in CKD17:30 - Implementation Science22:30 - Management Approach



